Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beyond Air Inc XAIR

Healthcare Medical Devices
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for... see more

Recent & Breaking News (NDAQ:XAIR)

Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire 7 days ago

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire 10 days ago

Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire 10 days ago

Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

GlobeNewswire October 29, 2024

Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire October 7, 2024

Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks

GlobeNewswire October 2, 2024

Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed

GlobeNewswire September 27, 2024

Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital

GlobeNewswire September 27, 2024

Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire September 27, 2024

Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GlobeNewswire September 23, 2024

Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire August 6, 2024

Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia

GlobeNewswire July 31, 2024

Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6

GlobeNewswire July 23, 2024

Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024

GlobeNewswire July 16, 2024

Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire June 24, 2024

Beyond Air® Appoints David Webster as Chief Commercial Officer

GlobeNewswire June 13, 2024

Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)

GlobeNewswire June 3, 2024

Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast

GlobeNewswire May 23, 2024

Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting

GlobeNewswire May 1, 2024

Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants

GlobeNewswire March 20, 2024